Home Tags Biotech
The biotech company is best known for its synthetic spider silk with its new synthetic leather material, Mylo, also on the rise. In the past couple of years, Bolt Threads has partnered with brands such as Patagonia, Best Made and most recently iconic English fashion designer Stella McCartney.
The FDA just approved a new kind of medication that could change the way we treat a condition that affects 38 million Americans
The drug, Aimovig, is the first of a new class of medications that's going after the huge migraine market. An estimated 38 million Americans have migraines, and a large portion — roughly 15 million— would be eligible for preventive treatment.
Sawing down desks and persevering through a hurricane— how one biotech startup is managing to stay in NYC
Starting a biotech in NYC can be rewarding, but it isn't always easy. An example is personalized reproductive health company Celmatix, which has stayed in the city for the past 9 years, despite cramped quarters and disruptions from a hurricane.
A cancer treatment that one expert called the ‘most exciting thing I’ve seen in my lifetime’ just got approved to treat more patient...
The FDA just approved a cutting-edge therapy to treat more patients with certain forms of blood cancer. It's the second approval for the drug, Kymriah, is now approved to treat certain forms of leukemia and lymphoma.
Prothena said on Monday that its drug to treat AL Amyloidosis failed a key trial, leading the company to discontinue a later-stage study.
Shire rejected a $60 billion bid from the Japanese drugmaker Takeda, while Allergan briefly considered getting into the fray on Thursday.
A startup that uses artificial intelligence to discover new drugs just landed a $2 billion valuation
BenevolentAI, a UK-based startup that uses artificial intelligence to discover new treatments just raised $115 million at a $2 billion valuation.
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
There could be a $35 billion market to treat NASH, a ‘silent disease’ millions are living with — and the competition’s startin...
Work's being done to pinpoint how to treat NASH, as well as research that's being used to better understand the genetics of the disease.
We’re about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
On Monday, three big players in the growing field of cancer immunotherapy are sharing data that could change how we treat lung cancer.